Loading...
The FDA is reminding clinicians of the potential risks for pancreatitis and thyroid C-cell tumors associated with the antidiabetes drug liraglutide (brand name, Victoza) after it recently learned that some primary care physicians were unaware of these warnings.
Patients taking liraglutide, a glucagon-like peptide-1 analog, were more likely to be diagnosed with pancreatitis than were those taking other diabetes medications. Patients should be observed for symptoms of pancreatitis after they start liraglutide or increase their dose.
In rodent studies, liraglutide was found to cause thyroid C-cell tumors, including medullary thyroid carcinoma, at clinically relevant dosage levels. The tumors increased with dose and treatment duration. The FDA has not concluded that liraglutide causes cancer in humans. Patients who develop thyroid nodules detected by neck imaging or physical exam or who have elevated serum calcitonin should be referred to an endocrinologist, but screening is not specifically recommended.
Comment
LINK(S):
FDA MedWatch alert (Free)